Navigation Links
Arpida Announces Agenda Items for Shareholders Meeting
Date:4/15/2008

authorised capital) or via conversion of bonds (conditional capital). Arpida currently has no intention to use this capital. This proposed additional capital cannot be used for the granting of employee options.

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent antibacterial that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been completed. The submission of the NDA to the US FDA was completed in March 2008.

In December 2007, Arpida announced the enrolment of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch could be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resi
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
2. Arpida Announces Full Year 2007 Financial Results
3. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
4. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
5. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
6. Arpida-Supported CME Symposium Available Online
7. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
8. Arpida Presents Preclinical Data on AR-2474 at ICAAC
9. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
10. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
11. Arpida Interim Results for six Months to 30 June 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Md., Sept. 30, 2014 BioHealth Innovation, ... commercializing market-relevant biohealth innovations and increasing access to early-stage ... today that venture capitalist, Tania Fernandez , Ph.D., ... Dr. Fernandez will be a member of the management ... provide up to $50 million in seed and early-stage ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 The custom ... ISPE Boston Product Show 2014. The Boston Area Chapter ... the 23rd annual, day-long event for Wed., Oct. 1 ... promises to be the largest in ISPE Boston’s long ... upward of 3,000 attendees expected. , HOLLOWAY AMERICA ...
(Date:9/30/2014)... 30, 2014 On September 11, Pharma IQ ... in anticipation of a session that he will lead on ... scheduled for February 17-18, 2015 in London. In the ... asked Dr. Sherley to respond to several questions on the ... to evaluating stem cell toxicity, and future trends in the ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 The ... IACRN), a non-profit organization based in Pittsburgh, ... Excellence and Safety (ACRES), a Massachusetts non-profit ... strategic alliance agreement, setting the stage for multiple ... enhance clinical research quality and safety through specialized ...
Breaking Biology Technology:Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3
... $235 Million, SOUTH SAN FRANCISCO, Calif., June 27 ... the company and,GlaxoSmithKline, Inc. (NYSE: GSK ) will ... 27, 2008, as scheduled. Under the,terms of the collaboration, ... of the,compounds in the collaboration for further development and,commercialization. ...
... world will present the latest breakthroughs in electro-optics, lasers ... Conference on Lasers and Electro-Optics/Quantum Electronics and Laser Science ... McEnery Convention Center in San Jose, Calif. , ... lasers and electro-optics community. It will be held in ...
... could be reduced by application of a simple polymer, ... injected into the blood stream as reported in ... , Andrew Koob and Richard Borgens from Purdue University, ... was effective in limiting damage if administered within four ...
Cached Biology Technology:Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration 2Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration 3Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration 4Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration 5Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 2Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 3Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 4Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 5Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 6Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 7
(Date:9/29/2014)... University of Texas at Arlington research team says recently ... in their lab could open doors for homeland security ... published in the Oct. 1 issue of Optics ... his co-authors describe a new method to fabricate transparent ... oxygen until a transparent ceramic is formed. A ...
(Date:9/29/2014)... Washington State University have concluded that nondigestible compounds ... may help prevent disorders associated with obesity. The ... these compounds in apple cultivars grown in the ... the journal Food Chemistry ., "We know ... of these nondigestible compounds but there are differences ...
(Date:9/29/2014)... found compounds that boost liver detoxification enzymes nearly fivefold, ... crushed seeds left after oil extraction from an oilseed ... in Camelina sativa seed, also known as ... that work together synergistically far better than they do ... because its bioactive ingredients increase the liver,s ability to ...
Breaking Biology News(10 mins):UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3An apple a day could keep obesity away 2New way to detox? 'Gold of Pleasure' oilseed boosts liver detoxification enzymes 2
... German Center for Neurodegenerative Diseases (DZNE) and the University ... "NLRP3 inflammasome" is composed of several proteins and plays ... a fire alarm sensor that triggers a chain reaction ... and substances that foster inflammation are released. This process ...
... 19, 2012) -- A new report in the journal ... vast, understudied swath of the animal kingdom that includes as ... genomes of a leech, an ocean-dwelling worm and a kind ... University, the University of California-Berkeley and the Department of Energy,s ...
... that badgers which strayed away from the family burrow in favour ... The 12-month study of 40 wild badgers was funded ... could have implications for the management of bovine TB in parts ... be a key factor in how the disease is spread among ...
Cached Biology News:Alzheimer's disease: Cutting off immune response promises new approach to therapy 2Genomic frontier: The unexplored animal kingdom 2Genomic frontier: The unexplored animal kingdom 3Badger sleeping habits could help target TB control 2
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap. (2/sp, 20/ca) Packaging: 2 / pack, 20 /...
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... a simple and convenient method for the rapid, ... been optimized for use with S. cerevisiae and ... fungus species that is susceptible to yeast lytic ... spheroplasts of yeast cells that are ideal for ...
Four siRNAs targeting your gene of interest, providing gene silencing with 100% satisfaction guaranteed High knockdown potency , High specificity for minimal off-target effects , Flexible siR...
Biology Products: